Cellebrite DI Ltd. Publishes Q1 2025 MD&A Report

Reuters
2025/05/15
<a href="https://laohu8.com/S/CLBT">Cellebrite</a> DI Ltd. Publishes Q1 2025 MD&A Report

Cellebrite DI Ltd. reported a strong 23% year-on-year growth in Annual Recurring Revenue $(ARR)$ for the first quarter, alongside a 34% increase in adjusted EBITDA, resulting in a 22% margin. This performance supported a Rule of X rating of 45 for the quarter and 48 over the trailing twelve months, aligning with the company's target range of 45-50. The company is focused on maintaining growth while managing spending to support bottom-line objectives. Key developments include robust year-over-year growth in ARR and revenue, driven by increasing demand from intelligence and defense sectors in response to the growing sophistication of digitally-enabled crime. Additionally, the company reported positive progress with its Inseyets migration and strategic penetration of its Guardian and Pathfinder products.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellebrite DI Ltd. published the original content used to generate this news brief on May 14, 2025, and is solely responsible for the information contained therein.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10